Onconase mediated NFKβ downregulation in malignant pleural mesothelioma

Treatment of malignant pleural mesothelioma (MPM) with Ranpirnase (Onconase) results in disruption of protein translation and cell apoptosis. We hypothesize that Onconase exerts an effect via downregulation of nuclear factor kappa B (NFKβ) by specific microRNAs (miRNAs) and that interference of this...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncogene 2011-06, Vol.30 (24), p.2767-2777
Hauptverfasser: Goparaju, C M, Blasberg, J D, Volinia, S, Palatini, J, Ivanov, S, Donington, J S, Croce, C, Carbone, M, Yang, H, Pass, H I
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2777
container_issue 24
container_start_page 2767
container_title Oncogene
container_volume 30
creator Goparaju, C M
Blasberg, J D
Volinia, S
Palatini, J
Ivanov, S
Donington, J S
Croce, C
Carbone, M
Yang, H
Pass, H I
description Treatment of malignant pleural mesothelioma (MPM) with Ranpirnase (Onconase) results in disruption of protein translation and cell apoptosis. We hypothesize that Onconase exerts an effect via downregulation of nuclear factor kappa B (NFKβ) by specific microRNAs (miRNAs) and that interference of this pathway could have implications for MPM resistance to chemotherapy. Three immortalized MPM cell lines (H2959, H2373 and H2591) were exposed to Onconase at 0–20 μg/ml. Cell counts were measured at 48 and 72 h. Gene expression in miRNA-enriched RNA was validated by reverse transcription–PCR (RT–PCR). The functional implications of miRNA expression were evaluated by transfecting miRNA mimics or inhibitors into MPM cell lines, and performing Matrigel invasion, cell proliferation, soft agar colony formation and scratch closure assays. Effects on NFKβ expression and downstream targets including ABC transporters, BCL-xl and IAP were assessed by RT–PCR and western blotting. Treatment with 20 μg/ml of Onconase significantly decreased cell count and invasion. Hsa-miR-17* was significantly upregulated and hsa-miR-30c was significantly downregulated by Onconase treatment in all cell lines. Forced expression of hsa-miR-17* mimic and hsa-miR-30c inhibitor each significantly decreased functional activity of Onconase in all assays. NFKB1 (p50) expression and downstream targets were also decreased with Onconase treatment, as well as with forced expression of miRNA mimic and inhibitors. Onconase treatment caused a significant decrease in cell proliferation, invasion and in expression of certain miRNAs. Recapitulation of the resultant miRNA expression pattern with hsa-miR-17* mimic and hsa-miR-30c inhibitor resulted in downregulation of NFKB1 and reduced malignant behavior in functional assays. Thus, Onconase likely exerts its antitumor effect through these miRNAs.
doi_str_mv 10.1038/onc.2010.643
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_876247200</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A259841873</galeid><sourcerecordid>A259841873</sourcerecordid><originalsourceid>FETCH-LOGICAL-c484t-24d4a02a233d6899186f501eed6a7f1fafd8fcfda55e7b702bc4033a31f623393</originalsourceid><addsrcrecordid>eNqN0c9rFDEUB_Agil2rN88yIOLFqS8_ZpI5ltJasdiLnsPbTLKmZJI1maH4b_UP8W8yy64uiAdPIeTz3svjS8hLCmcUuHqfojljUG-94I_IigrZt103iMdkBUMH7cA4OyHPSrkDADkAe0pOGOVUDkysyPVtNClisc1kR4-zHZvPV59-PjRjuo_ZbpaAs0-x8bGZMPhNxDg322CXjKGWlDR_s8GnCZ-TJw5DsS8O5yn5enX55eK6vbn98PHi_KY1Qom5ZWIUCAwZ52OvhoGq3nVArR17lI46dKNyxo3YdVauJbC1EcA5cur6WjPwU_J233eb0_fFlllPvhgbAkablqKV7JmQDOA_JBNcUKqqfP2XvEtLjnUNzXpB6wcEg6PaYLDaR5fmjGbXU5-zblCCKsmrerdXJqdSsnV6m_2E-YemoHeB6RqY3gWma2CVvzqMXtY1gT_4d0IVvDkALAaDyxiNL0cnODApaXXt3pX6FDc2H3f45-Bfj-6rEg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2641403420</pqid></control><display><type>article</type><title>Onconase mediated NFKβ downregulation in malignant pleural mesothelioma</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Nature Journals Online</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Goparaju, C M ; Blasberg, J D ; Volinia, S ; Palatini, J ; Ivanov, S ; Donington, J S ; Croce, C ; Carbone, M ; Yang, H ; Pass, H I</creator><creatorcontrib>Goparaju, C M ; Blasberg, J D ; Volinia, S ; Palatini, J ; Ivanov, S ; Donington, J S ; Croce, C ; Carbone, M ; Yang, H ; Pass, H I</creatorcontrib><description>Treatment of malignant pleural mesothelioma (MPM) with Ranpirnase (Onconase) results in disruption of protein translation and cell apoptosis. We hypothesize that Onconase exerts an effect via downregulation of nuclear factor kappa B (NFKβ) by specific microRNAs (miRNAs) and that interference of this pathway could have implications for MPM resistance to chemotherapy. Three immortalized MPM cell lines (H2959, H2373 and H2591) were exposed to Onconase at 0–20 μg/ml. Cell counts were measured at 48 and 72 h. Gene expression in miRNA-enriched RNA was validated by reverse transcription–PCR (RT–PCR). The functional implications of miRNA expression were evaluated by transfecting miRNA mimics or inhibitors into MPM cell lines, and performing Matrigel invasion, cell proliferation, soft agar colony formation and scratch closure assays. Effects on NFKβ expression and downstream targets including ABC transporters, BCL-xl and IAP were assessed by RT–PCR and western blotting. Treatment with 20 μg/ml of Onconase significantly decreased cell count and invasion. Hsa-miR-17* was significantly upregulated and hsa-miR-30c was significantly downregulated by Onconase treatment in all cell lines. Forced expression of hsa-miR-17* mimic and hsa-miR-30c inhibitor each significantly decreased functional activity of Onconase in all assays. NFKB1 (p50) expression and downstream targets were also decreased with Onconase treatment, as well as with forced expression of miRNA mimic and inhibitors. Onconase treatment caused a significant decrease in cell proliferation, invasion and in expression of certain miRNAs. Recapitulation of the resultant miRNA expression pattern with hsa-miR-17* mimic and hsa-miR-30c inhibitor resulted in downregulation of NFKB1 and reduced malignant behavior in functional assays. Thus, Onconase likely exerts its antitumor effect through these miRNAs.</description><identifier>ISSN: 0950-9232</identifier><identifier>EISSN: 1476-5594</identifier><identifier>DOI: 10.1038/onc.2010.643</identifier><identifier>PMID: 21317924</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/208/200 ; 631/337/384/331 ; 631/67/1059 ; 692/699/67/1641 ; Antineoplastic Agents - pharmacology ; Antitumor activity ; Apoptosis ; ATP Binding Cassette Transporter, Sub-Family B ; ATP-Binding Cassette, Sub-Family B, Member 1 - genetics ; Bcl-x protein ; Biological and medical sciences ; Cell Biology ; Cell growth ; Cell Line, Tumor ; Cell lines ; Cell physiology ; Cell proliferation ; Cell transformation and carcinogenesis. Action of oncogenes and antioncogenes ; Chemotherapy ; Development and progression ; Down-Regulation ; Drug resistance ; Fundamental and applied biological sciences. Psychology ; Gene expression ; Genetic aspects ; Human Genetics ; Humans ; Internal Medicine ; Medical sciences ; Medicine ; Medicine &amp; Public Health ; Mesothelioma ; Mesothelioma - drug therapy ; Mesothelioma - enzymology ; MicroRNA ; MicroRNAs ; MicroRNAs - analysis ; MicroRNAs - physiology ; miRNA ; Molecular and cellular biology ; NF-kappa B - antagonists &amp; inhibitors ; NF-kappa B - genetics ; NF-kappa B - physiology ; Oncology ; original-article ; Physiological aspects ; Pleural Neoplasms - drug therapy ; Pleural Neoplasms - enzymology ; Pneumology ; Reverse transcription ; Ribonucleases - pharmacology ; Transfection ; Tumors of the respiratory system and mediastinum ; Western blotting</subject><ispartof>Oncogene, 2011-06, Vol.30 (24), p.2767-2777</ispartof><rights>Macmillan Publishers Limited 2011</rights><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2011 Nature Publishing Group</rights><rights>Macmillan Publishers Limited 2011.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c484t-24d4a02a233d6899186f501eed6a7f1fafd8fcfda55e7b702bc4033a31f623393</citedby><cites>FETCH-LOGICAL-c484t-24d4a02a233d6899186f501eed6a7f1fafd8fcfda55e7b702bc4033a31f623393</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/onc.2010.643$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/onc.2010.643$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=24302771$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21317924$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goparaju, C M</creatorcontrib><creatorcontrib>Blasberg, J D</creatorcontrib><creatorcontrib>Volinia, S</creatorcontrib><creatorcontrib>Palatini, J</creatorcontrib><creatorcontrib>Ivanov, S</creatorcontrib><creatorcontrib>Donington, J S</creatorcontrib><creatorcontrib>Croce, C</creatorcontrib><creatorcontrib>Carbone, M</creatorcontrib><creatorcontrib>Yang, H</creatorcontrib><creatorcontrib>Pass, H I</creatorcontrib><title>Onconase mediated NFKβ downregulation in malignant pleural mesothelioma</title><title>Oncogene</title><addtitle>Oncogene</addtitle><addtitle>Oncogene</addtitle><description>Treatment of malignant pleural mesothelioma (MPM) with Ranpirnase (Onconase) results in disruption of protein translation and cell apoptosis. We hypothesize that Onconase exerts an effect via downregulation of nuclear factor kappa B (NFKβ) by specific microRNAs (miRNAs) and that interference of this pathway could have implications for MPM resistance to chemotherapy. Three immortalized MPM cell lines (H2959, H2373 and H2591) were exposed to Onconase at 0–20 μg/ml. Cell counts were measured at 48 and 72 h. Gene expression in miRNA-enriched RNA was validated by reverse transcription–PCR (RT–PCR). The functional implications of miRNA expression were evaluated by transfecting miRNA mimics or inhibitors into MPM cell lines, and performing Matrigel invasion, cell proliferation, soft agar colony formation and scratch closure assays. Effects on NFKβ expression and downstream targets including ABC transporters, BCL-xl and IAP were assessed by RT–PCR and western blotting. Treatment with 20 μg/ml of Onconase significantly decreased cell count and invasion. Hsa-miR-17* was significantly upregulated and hsa-miR-30c was significantly downregulated by Onconase treatment in all cell lines. Forced expression of hsa-miR-17* mimic and hsa-miR-30c inhibitor each significantly decreased functional activity of Onconase in all assays. NFKB1 (p50) expression and downstream targets were also decreased with Onconase treatment, as well as with forced expression of miRNA mimic and inhibitors. Onconase treatment caused a significant decrease in cell proliferation, invasion and in expression of certain miRNAs. Recapitulation of the resultant miRNA expression pattern with hsa-miR-17* mimic and hsa-miR-30c inhibitor resulted in downregulation of NFKB1 and reduced malignant behavior in functional assays. Thus, Onconase likely exerts its antitumor effect through these miRNAs.</description><subject>631/208/200</subject><subject>631/337/384/331</subject><subject>631/67/1059</subject><subject>692/699/67/1641</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antitumor activity</subject><subject>Apoptosis</subject><subject>ATP Binding Cassette Transporter, Sub-Family B</subject><subject>ATP-Binding Cassette, Sub-Family B, Member 1 - genetics</subject><subject>Bcl-x protein</subject><subject>Biological and medical sciences</subject><subject>Cell Biology</subject><subject>Cell growth</subject><subject>Cell Line, Tumor</subject><subject>Cell lines</subject><subject>Cell physiology</subject><subject>Cell proliferation</subject><subject>Cell transformation and carcinogenesis. Action of oncogenes and antioncogenes</subject><subject>Chemotherapy</subject><subject>Development and progression</subject><subject>Down-Regulation</subject><subject>Drug resistance</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Gene expression</subject><subject>Genetic aspects</subject><subject>Human Genetics</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Mesothelioma</subject><subject>Mesothelioma - drug therapy</subject><subject>Mesothelioma - enzymology</subject><subject>MicroRNA</subject><subject>MicroRNAs</subject><subject>MicroRNAs - analysis</subject><subject>MicroRNAs - physiology</subject><subject>miRNA</subject><subject>Molecular and cellular biology</subject><subject>NF-kappa B - antagonists &amp; inhibitors</subject><subject>NF-kappa B - genetics</subject><subject>NF-kappa B - physiology</subject><subject>Oncology</subject><subject>original-article</subject><subject>Physiological aspects</subject><subject>Pleural Neoplasms - drug therapy</subject><subject>Pleural Neoplasms - enzymology</subject><subject>Pneumology</subject><subject>Reverse transcription</subject><subject>Ribonucleases - pharmacology</subject><subject>Transfection</subject><subject>Tumors of the respiratory system and mediastinum</subject><subject>Western blotting</subject><issn>0950-9232</issn><issn>1476-5594</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqN0c9rFDEUB_Agil2rN88yIOLFqS8_ZpI5ltJasdiLnsPbTLKmZJI1maH4b_UP8W8yy64uiAdPIeTz3svjS8hLCmcUuHqfojljUG-94I_IigrZt103iMdkBUMH7cA4OyHPSrkDADkAe0pOGOVUDkysyPVtNClisc1kR4-zHZvPV59-PjRjuo_ZbpaAs0-x8bGZMPhNxDg322CXjKGWlDR_s8GnCZ-TJw5DsS8O5yn5enX55eK6vbn98PHi_KY1Qom5ZWIUCAwZ52OvhoGq3nVArR17lI46dKNyxo3YdVauJbC1EcA5cur6WjPwU_J233eb0_fFlllPvhgbAkablqKV7JmQDOA_JBNcUKqqfP2XvEtLjnUNzXpB6wcEg6PaYLDaR5fmjGbXU5-zblCCKsmrerdXJqdSsnV6m_2E-YemoHeB6RqY3gWma2CVvzqMXtY1gT_4d0IVvDkALAaDyxiNL0cnODApaXXt3pX6FDc2H3f45-Bfj-6rEg</recordid><startdate>20110616</startdate><enddate>20110616</enddate><creator>Goparaju, C M</creator><creator>Blasberg, J D</creator><creator>Volinia, S</creator><creator>Palatini, J</creator><creator>Ivanov, S</creator><creator>Donington, J S</creator><creator>Croce, C</creator><creator>Carbone, M</creator><creator>Yang, H</creator><creator>Pass, H I</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>P64</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20110616</creationdate><title>Onconase mediated NFKβ downregulation in malignant pleural mesothelioma</title><author>Goparaju, C M ; Blasberg, J D ; Volinia, S ; Palatini, J ; Ivanov, S ; Donington, J S ; Croce, C ; Carbone, M ; Yang, H ; Pass, H I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c484t-24d4a02a233d6899186f501eed6a7f1fafd8fcfda55e7b702bc4033a31f623393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>631/208/200</topic><topic>631/337/384/331</topic><topic>631/67/1059</topic><topic>692/699/67/1641</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antitumor activity</topic><topic>Apoptosis</topic><topic>ATP Binding Cassette Transporter, Sub-Family B</topic><topic>ATP-Binding Cassette, Sub-Family B, Member 1 - genetics</topic><topic>Bcl-x protein</topic><topic>Biological and medical sciences</topic><topic>Cell Biology</topic><topic>Cell growth</topic><topic>Cell Line, Tumor</topic><topic>Cell lines</topic><topic>Cell physiology</topic><topic>Cell proliferation</topic><topic>Cell transformation and carcinogenesis. Action of oncogenes and antioncogenes</topic><topic>Chemotherapy</topic><topic>Development and progression</topic><topic>Down-Regulation</topic><topic>Drug resistance</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Gene expression</topic><topic>Genetic aspects</topic><topic>Human Genetics</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Mesothelioma</topic><topic>Mesothelioma - drug therapy</topic><topic>Mesothelioma - enzymology</topic><topic>MicroRNA</topic><topic>MicroRNAs</topic><topic>MicroRNAs - analysis</topic><topic>MicroRNAs - physiology</topic><topic>miRNA</topic><topic>Molecular and cellular biology</topic><topic>NF-kappa B - antagonists &amp; inhibitors</topic><topic>NF-kappa B - genetics</topic><topic>NF-kappa B - physiology</topic><topic>Oncology</topic><topic>original-article</topic><topic>Physiological aspects</topic><topic>Pleural Neoplasms - drug therapy</topic><topic>Pleural Neoplasms - enzymology</topic><topic>Pneumology</topic><topic>Reverse transcription</topic><topic>Ribonucleases - pharmacology</topic><topic>Transfection</topic><topic>Tumors of the respiratory system and mediastinum</topic><topic>Western blotting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goparaju, C M</creatorcontrib><creatorcontrib>Blasberg, J D</creatorcontrib><creatorcontrib>Volinia, S</creatorcontrib><creatorcontrib>Palatini, J</creatorcontrib><creatorcontrib>Ivanov, S</creatorcontrib><creatorcontrib>Donington, J S</creatorcontrib><creatorcontrib>Croce, C</creatorcontrib><creatorcontrib>Carbone, M</creatorcontrib><creatorcontrib>Yang, H</creatorcontrib><creatorcontrib>Pass, H I</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health &amp; Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health &amp; Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied &amp; Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Oncogene</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goparaju, C M</au><au>Blasberg, J D</au><au>Volinia, S</au><au>Palatini, J</au><au>Ivanov, S</au><au>Donington, J S</au><au>Croce, C</au><au>Carbone, M</au><au>Yang, H</au><au>Pass, H I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Onconase mediated NFKβ downregulation in malignant pleural mesothelioma</atitle><jtitle>Oncogene</jtitle><stitle>Oncogene</stitle><addtitle>Oncogene</addtitle><date>2011-06-16</date><risdate>2011</risdate><volume>30</volume><issue>24</issue><spage>2767</spage><epage>2777</epage><pages>2767-2777</pages><issn>0950-9232</issn><eissn>1476-5594</eissn><abstract>Treatment of malignant pleural mesothelioma (MPM) with Ranpirnase (Onconase) results in disruption of protein translation and cell apoptosis. We hypothesize that Onconase exerts an effect via downregulation of nuclear factor kappa B (NFKβ) by specific microRNAs (miRNAs) and that interference of this pathway could have implications for MPM resistance to chemotherapy. Three immortalized MPM cell lines (H2959, H2373 and H2591) were exposed to Onconase at 0–20 μg/ml. Cell counts were measured at 48 and 72 h. Gene expression in miRNA-enriched RNA was validated by reverse transcription–PCR (RT–PCR). The functional implications of miRNA expression were evaluated by transfecting miRNA mimics or inhibitors into MPM cell lines, and performing Matrigel invasion, cell proliferation, soft agar colony formation and scratch closure assays. Effects on NFKβ expression and downstream targets including ABC transporters, BCL-xl and IAP were assessed by RT–PCR and western blotting. Treatment with 20 μg/ml of Onconase significantly decreased cell count and invasion. Hsa-miR-17* was significantly upregulated and hsa-miR-30c was significantly downregulated by Onconase treatment in all cell lines. Forced expression of hsa-miR-17* mimic and hsa-miR-30c inhibitor each significantly decreased functional activity of Onconase in all assays. NFKB1 (p50) expression and downstream targets were also decreased with Onconase treatment, as well as with forced expression of miRNA mimic and inhibitors. Onconase treatment caused a significant decrease in cell proliferation, invasion and in expression of certain miRNAs. Recapitulation of the resultant miRNA expression pattern with hsa-miR-17* mimic and hsa-miR-30c inhibitor resulted in downregulation of NFKB1 and reduced malignant behavior in functional assays. Thus, Onconase likely exerts its antitumor effect through these miRNAs.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>21317924</pmid><doi>10.1038/onc.2010.643</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0950-9232
ispartof Oncogene, 2011-06, Vol.30 (24), p.2767-2777
issn 0950-9232
1476-5594
language eng
recordid cdi_proquest_miscellaneous_876247200
source MEDLINE; SpringerLink Journals; Nature Journals Online; EZB-FREE-00999 freely available EZB journals
subjects 631/208/200
631/337/384/331
631/67/1059
692/699/67/1641
Antineoplastic Agents - pharmacology
Antitumor activity
Apoptosis
ATP Binding Cassette Transporter, Sub-Family B
ATP-Binding Cassette, Sub-Family B, Member 1 - genetics
Bcl-x protein
Biological and medical sciences
Cell Biology
Cell growth
Cell Line, Tumor
Cell lines
Cell physiology
Cell proliferation
Cell transformation and carcinogenesis. Action of oncogenes and antioncogenes
Chemotherapy
Development and progression
Down-Regulation
Drug resistance
Fundamental and applied biological sciences. Psychology
Gene expression
Genetic aspects
Human Genetics
Humans
Internal Medicine
Medical sciences
Medicine
Medicine & Public Health
Mesothelioma
Mesothelioma - drug therapy
Mesothelioma - enzymology
MicroRNA
MicroRNAs
MicroRNAs - analysis
MicroRNAs - physiology
miRNA
Molecular and cellular biology
NF-kappa B - antagonists & inhibitors
NF-kappa B - genetics
NF-kappa B - physiology
Oncology
original-article
Physiological aspects
Pleural Neoplasms - drug therapy
Pleural Neoplasms - enzymology
Pneumology
Reverse transcription
Ribonucleases - pharmacology
Transfection
Tumors of the respiratory system and mediastinum
Western blotting
title Onconase mediated NFKβ downregulation in malignant pleural mesothelioma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T14%3A13%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Onconase%20mediated%20NFK%CE%B2%20downregulation%20in%20malignant%20pleural%20mesothelioma&rft.jtitle=Oncogene&rft.au=Goparaju,%20C%20M&rft.date=2011-06-16&rft.volume=30&rft.issue=24&rft.spage=2767&rft.epage=2777&rft.pages=2767-2777&rft.issn=0950-9232&rft.eissn=1476-5594&rft_id=info:doi/10.1038/onc.2010.643&rft_dat=%3Cgale_proqu%3EA259841873%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2641403420&rft_id=info:pmid/21317924&rft_galeid=A259841873&rfr_iscdi=true